QGEN Qiagen NV: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization
Qiagen N.V. has secured high expert confidence through its status as a global leader in molecular diagnostics. The company's EV/EBITDA trajectory visualizes this stability via reduced volatility, with the value holding at 15.13. Business revenues are based on the sale of reagents and nucleic acid purification systems, while Thierry Bernard's strategy focuses on the automation of laboratory processes.
Analytical breakdowns for Qiagen N.V.
- current price and projected stock value:
- company stock capitalization data:
- book value of equity indicators:
- company total debt and liquidity indicators:
- net income and valuation multiples indicators:
QGEN - Annual Net Income|Projected Future Earnings Qiagen N.V.|QGEN - Market Cap to Earnings|Future Price to Earnings Qiagen Group|QGEN - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Qiagen Group|QGEN - Operating profit before amortization|Earnings per share for the last twelve months Qiagen|QGEN - Earnings per share for the last 12 months|Quarterly EPS earnings growth qiagen.com|QGEN - Earnings growth in current year|Net earnings per share growth forecast for next year Qiagen N.V.
- company sales and revenue statistics:
Summary company analytics:qiagen.com (QGEN)
For Qiagen N.V. (QGEN), a leader in the sample preparation segment, this indicator compares the total enterprise value of the business with its operating income. The metric assesses profit generation efficiency while accounting for debt load and tax obligations. By analyzing the EV/EBITDA level over a time interval, an investor can track the asset revaluation dynamics between reporting periods. The stability of this indicator confirms the company's strong pricing power, driven by the indispensability of its molecular biology technologies.
Analysis of competing companies
Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Tempus AI TEM|Total Company Value to Operating Income Before Depreciation Ratio Ionis (IONS)|repligen.com - EV/EBITDA Multiple|Company Value to EBITDA Avidity|CRSP (CRISPR Therapeutics Corp) - Enterprise Value to EBITDA Ratio|GeneDx Corp - Business Value to Operating Income Before Depreciation|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Ultragenyx|Company Value to EBITDA beamtx.com BEAM|Enterprise Value to EBITDA Ratio SRPT (Sarepta Therapeutics, Inc.)|TWST - Company Value to EBITDA|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization 10x TXG|Enterprise Value to Operating Income Before Depreciation Ratio NTLA (Intellia)|Stoke Corp - EV/EBITDA Multiple|BLFS: Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|WVE: EV/EBITDA Multiple|Company Value to EBITDA Maze Tx (MAZE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Sionna Therapeutics|Enterprise Value to Operating Income Before Depreciation PRME (Prime Medicine Corp)|EV/EBITDA Multiple TSHA|EV/EBITDA Multiple uniqure.com (QURE)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization MeiraGTx PLC MGTX|Business Value to Operating Income Before Depreciation RGNX|solidbio.com - EV/EBITDA Multiple|OCGN (Ocugen Pharma) - Enterprise Value to Operating Income Before Depreciation|PACB: EV/EBITDA Multiple|Benitec Biopharma (BNTC) - EV/EBITDA Multiple|DSGN (Design Therapeutics Inc) - EV/EBITDA Multiple|Rocket Pharmaceuticals, Inc. (RCKT) - Total Company Value to Operating Income Before Depreciation Ratio|FDMT - Company Value to Operating Income Before Depreciation Ratio|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization LXEO (Lexeo)|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization korrobio.com KRRO|Total Company Value to Operating Income Before Depreciation Ratio Editas Medicine, Inc. (EDIT)|SLN - Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization|Total Company Value to Operating Income Before Depreciation Ratio ProQR PRQR|CDXS: EV/EBITDA Multiple|Enterprise Value to EBITDA Multiple Sangamo BioSciences SGMO|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Nautilus Bio|MGX (Metagenomi, Inc.) - Enterprise Value to Operating Income Before Depreciation Ratio|EV/EBITDA Multiple DTIL|Generation Bio - Enterprise Value to Operating Income Before Depreciation|EV/EBITDA Multiple BOLD (Boundless Bio Inc.)|Business Value to Operating Income Before Depreciation XCUR|Imunon Inc - EV/EBITDA Multiple|PHIO (phiopharma.com) - Enterprise Value to Operating Income Before Depreciation|MBIO (mustangbio.com) - Enterprise Value to EBITDA Ratio|Enterprise Value to Operating Income Before Depreciation RNAZ|BNGO (Bionano) - EV/EBITDA Multiple|EV/EBITDA Multiple Applied DNA Corp|EV/EBITDA Multiple BLUE|EV/EBITDA Multiple ImmunoPrecise Antibodies Ltd. (IPA)|EV/EBITDA Multiple OMGA (omegatherapeutics.com)|OMIC: Enterprise Value to Operating Income Before Depreciation|RGLS: Enterprise Value to EBITDA Ratio|Business Value to Operating Income Before Depreciation SYRS (Syros Pharmaceuticals, Inc)|TBIO: EV/EBITDA Multiple|TRACON Pharmaceuticals (TCON) - EV/EBITDA Multiple|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Unity Biotechnology, Inc
